Chembio, founded in 1985, develops, manufactures, licenses, and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases and other medical conditions.
Chembio participates in the global HIV/Syphilis rapid testing market with strategic channel partners worldwide. We are now expanding distribution channels.
Chembio manufactures several U.S. FDA-approved, CE-Marked, WHO Prequalified and USAID Approved HIV 1/2 and Syphilis tests and just launched the DPP® Zika IgM/IgG System (Assay and Reader), CE-marked.
Chembio’s DPP® HIV 1/2 Assay works on oral fluid or any blood matrix and is based on our proprietary Next Generation DPP® Technology Dual Path Platform technology. It detects the presence of HIV 6 days earlier than the current oral fluid rapid test. DPP® technology enables multiplexing and improved sensitivity.
Chembio also offers a USAID Approved rapid DPP® HIV-Syphilis assay – a dual test requiring only one patient fingerstick sample of 10 µL.
Chembio's other FDA, CE-marked, WHO Prequalified and USAID Approved products, such as HIV 1/2 STAT-PAK®, HIV 1/2 STAT-PAK® DIPSTICK, CE-marked STAT-VIEW® HIV 1/2, and HIV 1/2 SURE CHECK® Assays for blood are widely used in rapid HIV testing in the field. They require very small blood samples, as small as 2.5 µL, and have a high degree of sensitivity and specificity. The tests are also very easy to perform. HIV 1/2 STAT-PAK® DIPSTICK, priced for resource-limited markets, is the lowest cost product in our portfolio. Our products are manufactured in the U.S.